Lupin plans to launch 3-4 generic drugs in U.S. by end-March

MUMBAI Thu Jan 31, 2013 3:06pm IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Lupin Ltd(LUPN.NS), India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.

The Mumbai-based drugmaker has so far launched six products in this fiscal year in the United States, which generates about 42 percent of its total formulation sales.

The drugmaker earlier reported a forecast-beating 42.6 percent rise in quarterly net profit to 3.35 billion rupees.

(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)

FILED UNDER:

Reuters Showcase

Trading Fees

Trading Fees

BSE slashes fees in FX derivatives battle with NSE  Full Article 

SpiceJet Turnaround

SpiceJet Turnaround

SpiceJet board approves up to $243 mln share sale plan  Full Article 

Currency Market

Currency Market

RBI urges companies to hedge FX exposure  Full Article 

Uber's Woes

Uber's Woes

Uber, other taxi-hailing apps hit new roadblock in Delhi.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage